National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 2) (PB 16 of 2021) (Cth)

PB 16 of 2021

National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 2)

I, THEA CONNOLLY, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, and delegate of the Minister for Health and Aged Care make the following determination.

Dated    24 February                2021

THEA CONNOLLY  

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

Contents

1...... Name

2...... Commencement............................................................................................................................... 1

3...... Authority......................................................................................................................................... 1

4 ..... Schedule.......................................................................................................................................... 1

Schedule 1—Amendments   2

National Health (Continued Dispensing - Emergency Measures) Determination 2020         2

1  Name

(1) This instrument is the National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 2).

(2) This instrument may also be cited as PB 16 of 2021.

2  Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1.  The whole of this instrument	1 March 2021.

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2)  Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

This instrument is made under subsection 89A(3) of the National Health Act 1953.

4  Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Continued Dispensing – Emergency Measures) Determination 2020

1. Schedule 1, omit entry for Amino acid formula with fat, carbohydrate, vitamins, minerals and long chain polyunsaturated fatty acids without phenylalanine and supplemented with docosahexaenoic acid

1. Schedule 1, after entry for Amino acid formula with vitamins and minerals without methionine in the form Sachets containing oral powder 25 g, 30 (HCU express 15)

insert:

Sachets containing oral powder 29 g, 30 (HCU Lophlex) Oral

1. Schedule 1, after entry for Amino acid formula with vitamins and minerals without phenylalanine and tyrosine in the form Sachets containing oral powder 25 g, 30 (TYR express 15)

insert:

Sachets containing oral powder 28 g, 30 (TYR Lophlex) Oral

1. Schedule 1, after entry for Amino acid formula with vitamins and minerals without valine, leucine and isoleucine in the form Sachets containing oral powder 25 g, 30 (MSUD express 15)

insert:

Sachets containing oral powder 28 g, 30 (MSUD Lophlex) Oral

1. Schedule 1, entry for Captopril

omit:

Tablet 12.5 mg Oral

1. Schedule 1, omit entry for Cefalotin

1. Schedule 1, omit entry for Cimetidine

1. Schedule 1, after entry for Desmopressin in the form Intranasal solution containing desmopressin acetate 100 micrograms per mL, 2.5 mL dropper bottle  

insert:

Nasal spray (pump pack) containing desmopressin acetate 10 micrograms per actuation, 50 actuations,
5 mL Nasal

1. Schedule 1, after entry for Duloxetine in the form Capsule 60 mg (as hydrochloride)

insert:

Dupilumab	Injection 200 mg in 1.14 mL single dose pre-filled syringe	Injection
Injection 300 mg in 2 mL single dose pre-filled syringe	Injection

1. Schedule 1, entry for Erythromycin

omit:

Tablet 400 mg (as ethyl succinate) Oral

1. Schedule 1, omit entry for Grazoprevir with elbasvir

1. Schedule 1, after entry for Indacaterol with glycopyrronium

insert:

Indacaterol with mometasone	Capsule containing powder for oral inhalation indacaterol 125 micrograms (as acetate) with mometasone furoate 62.5 micrograms (for use in Breezhaler)	Inhalation by mouth
Capsule containing powder for oral inhalation indacaterol 125 micrograms (as acetate) with mometasone furoate 127.5 micrograms (for use in Breezhaler)	Inhalation by mouth
Capsule containing powder for oral inhalation indacaterol 125 micrograms (as acetate) with mometasone furoate 260 micrograms (for use in Breezhaler)	Inhalation by mouth

1. Schedule 1, omit entry for Metformin with glibenclamide

1. Schedule 1, after entry for Oxycodone with naloxone in the form Tablet (controlled release) containing oxycodone hydrochloride 80 mg with naloxone hydrochloride 40 mg

insert:

Ozanimod	Capsule 920 micrograms	Oral
Pack containing 4 capsules 230 micrograms and 3 capsules 460 micrograms	Oral

1. Schedule 1, omit entry for Sucralfate

1. Schedule 1, entry for Tamoxifen

omit:

Tablet 10 mg (as citrate) Oral

1. Schedule 1, entry for Verapamil

omit:

Tablet containing verapamil hydrochloride 40 mg Oral